Vitamin Profile of the Patients with Chronic Kidney Disease Receiving a Novel Total Parenteral Nutrition Formula: Multicenter Randomized Controlled Phase III Trial.

IF 2.9 3区 医学 Q2 ENDOCRINOLOGY & METABOLISM
Ken Tsuchiya, Tatsukuni Kawakami, Yusuke Maniwa, Yoshiyuki Kawauchi, Motofusa Katayama
{"title":"Vitamin Profile of the Patients with Chronic Kidney Disease Receiving a Novel Total Parenteral Nutrition Formula: Multicenter Randomized Controlled Phase III Trial.","authors":"Ken Tsuchiya, Tatsukuni Kawakami, Yusuke Maniwa, Yoshiyuki Kawauchi, Motofusa Katayama","doi":"10.1159/000547656","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Efficacy and safety of a novel total parenteral nutrition formula for chronic kidney disease patients, OPF-109, containing multivitamins based on the FDA2000 recommendation were investigated.</p><p><strong>Methods: </strong>We conducted a phase III clinical trial administering OPF-109 (n=63) or the control solutions (combination of marketed products including multivitamin based on American Medical Association 1975 guidelines) (n=61) to the chronic kidney disease patients for 8 days. Blood concentrations of proteins and vitamins and safety were evaluated. The primary efficacy endpoint was protein concentration (serum T-P, ALB, pre-ALB, transferrin) on Day8. Safety endpoints were hematological data, blood biochemistry data, vital signs, and adverse events.</p><p><strong>Results: </strong>Values of blood protein until Day8 were similar in 2 groups although those of vitamins B1, B6, C, and folic acid (contained more in OPF-109) were higher in the OPF-109 group. For both groups, vitamin C concentration of Day1 was below the normal range, which restored to within the range in the OPF-109 group but decreased in the control group on Day8. Vitamin K concentration (contained less in OPF-109) was over the normal range on Day1 in both groups and decreased to slightly higher than the normal range in the OPF-109 group while increased to higher than Day1 value in the control group on Day8. Safety was similar in 2 groups.</p><p><strong>Conclusion: </strong>Efficacy and safety of OPF-109 and usefulness of multivitamins based on the FDA 2000 recommendations formula were confirmed in chronic kidney disease patients.</p>","PeriodicalId":8269,"journal":{"name":"Annals of Nutrition and Metabolism","volume":" ","pages":"1-27"},"PeriodicalIF":2.9000,"publicationDate":"2025-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Nutrition and Metabolism","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000547656","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Efficacy and safety of a novel total parenteral nutrition formula for chronic kidney disease patients, OPF-109, containing multivitamins based on the FDA2000 recommendation were investigated.

Methods: We conducted a phase III clinical trial administering OPF-109 (n=63) or the control solutions (combination of marketed products including multivitamin based on American Medical Association 1975 guidelines) (n=61) to the chronic kidney disease patients for 8 days. Blood concentrations of proteins and vitamins and safety were evaluated. The primary efficacy endpoint was protein concentration (serum T-P, ALB, pre-ALB, transferrin) on Day8. Safety endpoints were hematological data, blood biochemistry data, vital signs, and adverse events.

Results: Values of blood protein until Day8 were similar in 2 groups although those of vitamins B1, B6, C, and folic acid (contained more in OPF-109) were higher in the OPF-109 group. For both groups, vitamin C concentration of Day1 was below the normal range, which restored to within the range in the OPF-109 group but decreased in the control group on Day8. Vitamin K concentration (contained less in OPF-109) was over the normal range on Day1 in both groups and decreased to slightly higher than the normal range in the OPF-109 group while increased to higher than Day1 value in the control group on Day8. Safety was similar in 2 groups.

Conclusion: Efficacy and safety of OPF-109 and usefulness of multivitamins based on the FDA 2000 recommendations formula were confirmed in chronic kidney disease patients.

接受一种新型全肠外营养配方的慢性肾病患者的维生素概况:多中心随机对照III期试验
基于FDA2000推荐的一种新型含多种维生素的慢性肾病患者全肠外营养配方OPF-109的疗效和安全性进行了研究。方法:我们进行了一项III期临床试验,对慢性肾病患者给予OPF-109 (n=63)或对照溶液(根据美国医学协会1975年指南,包括多种维生素在内的上市产品组合)(n=61) 8天。评估血液中蛋白质和维生素的浓度及安全性。主要疗效终点为第8天的蛋白浓度(血清T-P、ALB、ALB前期、转铁蛋白)。安全性终点包括血液学数据、血液生化数据、生命体征和不良事件。结果:两组至第8天的血蛋白值相近,但OPF-109组的维生素B1、B6、C和叶酸含量较高(OPF-109中含有较多叶酸)。两组维生素C浓度在第1天均低于正常范围,OPF-109组维生素C浓度在第8天恢复到正常范围内,对照组维生素C浓度下降。两组维生素K浓度(OPF-109中含量较少)在第1天均超过正常范围,OPF-109组维生素K浓度在第8天下降至略高于正常范围,而对照组维生素K浓度在第8天上升至高于正常范围。两组的安全性相似。结论:OPF-109在慢性肾病患者中的有效性和安全性以及基于FDA 2000推荐配方的复合维生素的有效性得到了证实。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Annals of Nutrition and Metabolism
Annals of Nutrition and Metabolism 医学-内分泌学与代谢
CiteScore
6.50
自引率
0.00%
发文量
55
审稿时长
6-12 weeks
期刊介绍: ''Annals of Nutrition and Metabolism'' is a leading international peer-reviewed journal for sharing information on human nutrition, metabolism and related fields, covering the broad and multidisciplinary nature of science in nutrition and metabolism. As the official journal of both the International Union of Nutritional Sciences (IUNS) and the Federation of European Nutrition Societies (FENS), the journal has a high visibility among both researchers and users of research outputs, including policy makers, across Europe and around the world.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信